| Literature DB >> 19011342 |
Kyoko Obayashi1, Susumu Ohwada, Yutaka Sunose, Koujirou Yamamoto, Rie Igarashi, Kunihiro Hamada, Izumi Takeyoshi, Ryuya Horiuchi.
Abstract
Gemcitabine(GEM)is the standard therapy for advanced pancreatic cancer. GEM-oxaliplatin (GEMOX) combination treatment has been reported to be superior to GEM alone in terms of clinical progression-free survival, but it is not the therapy of choice for pancreatic cancer. We report a case of advanced mucinous cystic neoplasm (MCN) of the pancreas with multiple hepatic metastases in a 39-year-old female. She was treated with 16 courses of GEMOX (GEM 1,500 mg/day at a rate of 10 mg/m2/min on the first day and oxaliplatin 150 mg/day at 100 mg/m2 on the second day, every 3 weeks). The pharmacist helped her to avoid severe side effects. When the hepatic metastases disappeared after 13 courses, the primary MCN was removed surgically after 16 courses of GEMOX treatment. No recurrence has been observed 22 months postoperatively. GEMOX might be effective for the treatment of MCN of the pancreas.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19011342
Source DB: PubMed Journal: Gan To Kagaku Ryoho ISSN: 0385-0684